Navigation Links
Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2007 Financial Results
Date:2/19/2008

The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities and clinical trials, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. Government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
2. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
3. Human Genome Sciences and Xencor Announce Antibody Collaboration
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
5. Stemagen First to Create Cloned Human Embryos From Adult Cells
6. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
7. International team identifies 480 genes that control human cell division
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
9. Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board
10. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
11. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ... M.D., President and Chief Executive Officer, will present at the ... in New York on Tuesday, Sept. ... live and archived webcast of the presentation will be accessible ... "News & Events" section. About Oncothyreon ...
(Date:9/2/2014)... 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... orders consist of three large odour control systems for waste ... "These orders are consistent with the market resurgence in ... , President and CEO. "After a difficult period of restraint ... beginning to see sales growth. Our lower cost structure, technology ...
(Date:9/2/2014)... BETHESDA, Md. , Sept. 2, 2014  Spherix ... fostering and monetization of intellectual property, today announced that ... three patents to the Company in the month of ... of patents.  The issued patents are: ... , U.S.RE45,081 issued August 19, 2014; and ...
(Date:9/2/2014)... Melbourne, Victoria, Australia (PRWEB) September 02, 2014 ... may provide a cure for chronic tinnitus are seeking ... campaign, run on the Indiegogo platform ( http://igg.me/at/tinaway ), ... designed to be a therapeutic ‘mHealth’ app and is ... the brainchild of a team of biomedical and software ...
Breaking Biology Technology:United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... -- China Medicine,Corporation (OTC Bulletin Board: ... leading distributor and developer of prescription ... nutritional and,dietary supplements, medical devices, and ... China ("PRC"), through its wholly-owned U.S,subsidiary, ...
... individual risk of basal,cell carcinoma, and are integrated ... Iceland, Oct. 13 Scientists at,deCODE genetics (Nasdaq: ... common,versions of two single-letter variations in the human ... (BCC), the most common cancer among,people of European ...
... In March 2007, Joe Weitz left his position ... Cables to Go/Lastar Inc. to form American Consumer ... States Air Force veterans he partners with at ... online providers of technology-based connectivity solutions; one that ...
Cached Biology Technology:China Medicine to Showcase 'Bethin' Weight Loss Product at 2008 Natural Products Expo East Trade Show 2China Medicine to Showcase 'Bethin' Weight Loss Product at 2008 Natural Products Expo East Trade Show 3deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 2deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 3deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 4 Former Cables to Go/Lastar Inc. Employee's Move to Form American Consumer Cables Pays Off 2
(Date:9/2/2014)... American Society of Human Genetics (ASHG) and the ... the National Institutes of Health, have named Elizabeth ... The Wellington School in Columbus, Ohio, the first ... begins today. , The Genetics and Education Fellowship ... their skills, experience, and network to prepare for ...
(Date:9/2/2014)... of University of Maryland physicists has published new ... make possible new nanostructures and nanotechnologies with huge ... computing advances to new sensor development. , Published ... Communications the Maryland scientists, primary discovery is ... that uses a connector, or "intermedium," nanoparticle to ...
(Date:9/2/2014)... In a new study that could ultimately lead to ... The Scripps Research Institute (TSRI) have adapted a chemical ... for molecules that can treat a form of muscular ... vessel and a disease-causing defect as a catalyst to ... Professor Matthew Disney.,"Because the treatment is synthesized only in ...
Breaking Biology News(10 mins):ASHG and NHGRI award first genetics and education fellowship 2New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3Scripps Florida scientists make diseased cells synthesize their own drug 2
... escape from captivity they could succeed in breeding and ... found. Their research, published in Evolutionary Applications , ... they are considered for commercial farming. "The ... interest to the aquaculture industry and now genetically modified ...
... to getting our ,body clocks, back in sync and now ... discovered a molecule essential to the process. Researchers ... of light on the circadian clocks (commonly known as ,body ... (QSM), which was intrinsically involved in relaying light-information to the ...
... Kenneth Walsh, PhD, FAHA, the Aram V. ... the Whitaker Cardiovascular Institute at Boston University School ... American Heart Association (AHA) Distinguished Scientist. The AHA ... The AHA created a Distinguished Scientist designation in ...
Cached Biology News:First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool 2Newly discovered molecule essential to resetting 'body clocks' 2BUSM professor selected as American Heart Association Distinguished Scientist 2
... PhosphoPlus™ SAPK/JNK (Thr183/Tyr185) Antibody Kit ... Antibody, Catalog #9251, 200 ul SAPK/JNK ... ul SAPK/JNK Cell Extracts, Catalog #9253, ... Antibody, Catalog #7074, 100 ul Anti-biotin ...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
...
Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
Biology Products: